Key Highlights

  • Bioceres Crop Solutions reported full fiscal year 2026 Revenue of 238 million dollars, down 18 percent year over year, though fourth quarter revenue of 55.9 million dollars was roughly stable versus the prior year.
  • Fourth quarter adjusted EBITDA improved by approximately 10 million dollars year over year, turning positive at 0.6 million dollars from negative 9.6 million dollars.
  • The company successfully reprofiled approximately 28 million dollars of bank Debt at its Rizobacter Subsidiary and completed a voluntary Maturity extension covering 46.5 million dollars of local bonds in Argentina.
  • Management is targeting approximately 40 percent gross margins for fiscal 2027 and beyond, focusing growth on higher-quality core revenue streams, particularly in Brazil.

A challenging year marked by litigation and portfolio reconfiguration

Bioceres Crop Solutions Corp. (NASDAQ:BIOX), a Rosario, Argentina-based agricultural biotechnology company, reported fiscal year 2026 results reflecting the continued impact of ongoing litigation with certain creditors alongside a multi-year reconfiguration of its seed business. Revenue from continuing operations declined 18 percent to 238 million dollars for the full year, with approximately half of that decline associated with the previously announced seed Business reconfiguration and most of the remainder concentrated in the Crop Protection segment.

Full year reported Gross Profit was 82.9 million dollars, down 21 percent, with gross Margin of 34.8 percent, a figure management said was significantly affected by a non-recurring inventory obsolescence charge and the ongoing wind-down of the legacy seed business model. Total financial debt stood at 225.9 million dollars as of June 30, broadly stable compared with the end of the third quarter, with net financial debt of 213.6 million dollars after accounting for 12.2 million dollars of cash and short-term investments.

Fourth quarter cost actions drive a return to positive EBITDA

Fourth quarter revenue of 55.9 million dollars was slightly above the 55.4 million dollars reported in the prior year period, with growth concentrated in the Crop Nutrition segment, which increased 36 percent year over year on strong performance from microbeaded fertilizer products. This growth was partially offset by lower revenues in Crop Protection and Seeds, though management noted that underlying profitability across several core product categories improved even where reported figures were masked by one-time items.

The clearest evidence of progress came at the adjusted EBITDA line, which improved by approximately 10 million dollars year over year to a positive 0.6 million dollars from negative 9.6 million dollars, driven primarily by a 19 percent reduction in selling, general and administrative expenses. For the full year, adjusted EBITDA was 25.5 million dollars compared with 28.9 million dollars in fiscal 2025, with management emphasizing that despite an 18 percent revenue decline and 21 percent decline in reported gross profit, adjusted EBITDA declined only 12 percent, reflecting the scale of the more than 20 million dollar reduction in operating expenses achieved during the year.

Balancing margin targets against unresolved litigation risk

If the company's plan to rationalize its product portfolio toward higher-margin, higher-quality revenue streams succeeds, particularly in Brazil, management believes approximately 40 percent gross margins are achievable for fiscal 2027 and beyond, supported by the fact that 99 percent of the company's aggregated fiscal 2025 gross profit came from less than half of its total product catalog. A targeted combined selling, general and administrative expense ratio of 23 percent of revenue by fiscal 2028 could further support profitability if the company's ongoing systems implementation and organizational simplification efforts proceed as planned.

Significant risk remains tied to the company's ongoing dispute with noteholders in New York, where substantially all of the related secured notes, approximately 118.6 million dollars at year end, remain classified as Short-Term Debt following an acceleration notice that the company continues to dispute alongside an associated foreclosure process. While the company made meaningful progress reprofiling other debt obligations, including 28 million dollars of Rizobacter bank debt and 46.5 million dollars of local Argentine bonds, the unresolved secured note litigation represents a material overhang on the company's Capital Structure and financial flexibility.

Early signs of stabilization amid unresolved legal uncertainty

Bioceres Crop Solutions' fiscal 2026 results reflect a company navigating a difficult combination of declining revenue, ongoing creditor litigation, and a multi-year seed business restructuring, while simultaneously making tangible progress on cost discipline that returned the fourth quarter to positive adjusted EBITDA. Successful debt reprofiling at the Rizobacter subsidiary and in local Argentine markets demonstrates the company's ability to manage portions of its capital structure even amid broader financial pressure. Whether the unresolved New York noteholder litigation can be favorably resolved, and whether targeted margin improvements materialize as the seed business transition concludes, will likely determine the pace of the company's recovery through fiscal 2027.